NCBI Logo
GEO Logo
   NCBI > GEO > Accession DisplayHelp Not logged in | LoginHelp
GEO help: Mouse over screen elements for information.
          Go
Series GSE216130 Query DataSets for GSE216130
Status Public on Sep 05, 2023
Title Attenuated IL-2 muteins promote regulatory T cell adaptation of the effector phenotype and function in vivo via modified IL-2 responses
Organism Mus musculus
Experiment type Expression profiling by high throughput sequencing
Summary Interleukin-2 (IL-2), along with T-cell receptor (TCR) signaling, are required to control regulatory T cell (Treg) homeostasis and function in vivo. Due to the heightened sensitivity to IL-2, Tregs retain the ability to respond to low-dose or attenuated forms of IL-2, as currently being developed for clinical use to treat inflammatory diseases. While attenuated IL-2 increases Treg selectivity, the question remains as to whether a weakened IL-2 signal sufficiently enhances Treg suppressive function(s) toward disease modification. To understand this question, we characterized the in vivo activity and transcriptomic profiles of two different attenuated IL-2 muteins in comparison with wildtype (WT) IL-2. Our study showed that, in addition to favoring Tregs, the attenuated muteins induced disproportionately robust effects on Treg activation and conversion to effector Treg (eTreg) phenotype. Our data furthermore suggested that Tregs activated by attenuated IL-2 muteins showed reduced dependence on TCR signal, at least in part due to the enhanced ability of IL-2 muteins to amplify the TCR signal in vivo. These results point to a new paradigm wherein IL-2 influences Tregs’ sensitivity to antigenic signal, and that the combination effect may be leveraged for therapeutic use of attenuated IL-2 muteins.
 
Overall design Four different IL-2 treatment conditions (PBS, WT IL-2, H16R, and 3x mutein) within 2 antibody treatment groups (isotype and MHC II blocking antibodies) were evaluated with 4 mice in each group, resulting in a total of 32 Treg samples. CD25- Tcons from two mice from each group were included for comparison.
 
Contributor(s) Ma S, So M, Ghelani A, Srivas R, Sahoo A, Hall R, Liu W, Wu H, Yu S, Lu S, Song E, Cariaga T, Soto M, Zhou H, Li C, Chaudhry A, Luo X, Sohn SJ
Citation(s) 37809101
Submission date Oct 19, 2022
Last update date Oct 18, 2023
Contact name Shining Ma
E-mail(s) sma05@amgen.com
Organization name Amgen Inc.
Street address 1120 Veterans Blvd
City South San Francisco
State/province CA
ZIP/Postal code 94080
Country USA
 
Platforms (1)
GPL30172 NextSeq 2000 (Mus musculus)
Samples (48)
GSM6659039 1_A1-1 Treg,Isotype,PBS
GSM6659040 2_A1-2 Treg,Isotype,PBS
GSM6659041 3_A1-3 Treg,Isotype,PBS
Relations
BioProject PRJNA892130

Download family Format
SOFT formatted family file(s) SOFTHelp
MINiML formatted family file(s) MINiMLHelp
Series Matrix File(s) TXTHelp

Supplementary file Size Download File type/resource
GSE216130_Treg_Isotype_DEG_ByDESeq2.csv.gz 2.7 Mb (ftp)(http) CSV
GSE216130_Treg_MHC_II_DEG_ByDESeq2.csv.gz 2.7 Mb (ftp)(http) CSV
GSE216130_Treg_sample_treatment_comparison_DEG_ByDESeq2.csv.gz 1.9 Mb (ftp)(http) CSV
GSE216130_gene_Counts_Matrix.txt.gz 2.7 Mb (ftp)(http) TXT
GSE216130_gene_FPKM_Matrix.txt.gz 3.6 Mb (ftp)(http) TXT
SRA Run SelectorHelp
Raw data are available in SRA
Processed data are available on Series record

| NLM | NIH | GEO Help | Disclaimer | Accessibility |
NCBI Home NCBI Search NCBI SiteMap